Literature DB >> 27616591

Growth charts for individuals with rhizomelic chondrodysplasia punctata.

Angela L Duker1, Tim Niiler2, Grant Eldridge3, Nga H Brereton4, Nancy E Braverman5, Michael B Bober1.   

Abstract

Rhizomelic chondrodysplasia punctata (RCDP) is a class of peroxisomal disorders characterized by defective plasmalogen biosynthesis. There are multiple recognized types of RCDP, all of which have autosomal recessive inheritance, and their associated genes are known: RCDP type 1 with PEX7, RCDP type 2 with GNPAT, RCDP type 3 with AGPS, RCDP type 4 with FAR1, and RCDP type 5 with PEX5. Among other medical/developmental issues, plasmalogen deficiency has a direct effect on bone growth and results in postnatal growth failure, the severity of which corresponds to the degree of plasmalogen deficiency. In order to document growth in patients with RCDP, we present detailed growth curves for length, weight, and head circumference derived from retrospective data from 23 individuals with RCDP types 1 and 2 confirmed by molecular and/or biochemical studies. We stratified growth curves by age as well as by plasmalogen level, with those with higher plasmalogens grouped as "non-classic." The growth charts presented here provide guidance to families and physician caretakers on the natural course of growth in individuals with RCDP during infancy into early childhood, and thus will have particular utility in setting expectations and guiding optimal feeding interventions in this population.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  RCDP; growth charts; rhizomelic chondrodysplasia punctata; skeletal dysplasia

Mesh:

Year:  2016        PMID: 27616591     DOI: 10.1002/ajmg.a.37961

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  7 in total

Review 1.  Peroxisomes of the Brain: Distribution, Functions, and Associated Diseases.

Authors:  Rachayeeta Deb; Neha Joshi; Shirisha Nagotu
Journal:  Neurotox Res       Date:  2021-01-05       Impact factor: 3.911

2.  Pharmacokinetics, Mass Balance, Excretion, and Tissue Distribution of Plasmalogen Precursor PPI-1011.

Authors:  Tara Smith; Kaeli J Knudsen; Shawn A Ritchie
Journal:  Front Cell Dev Biol       Date:  2022-04-25

Review 3.  From peroxisomal disorders to common neurodegenerative diseases - the role of ether phospholipids in the nervous system.

Authors:  Fabian Dorninger; Sonja Forss-Petter; Johannes Berger
Journal:  FEBS Lett       Date:  2017-09-07       Impact factor: 4.124

4.  Clinical diagnosis of metabolic disorders using untargeted metabolomic profiling and disease-specific networks learned from profiling data.

Authors:  Lillian R Thistlethwaite; Xiqi Li; Lindsay C Burrage; Kevin Riehle; Joseph G Hacia; Nancy Braverman; Michael F Wangler; Marcus J Miller; Sarah H Elsea; Aleksandar Milosavljevic
Journal:  Sci Rep       Date:  2022-04-21       Impact factor: 4.996

5.  A Novel Variant in the AGPS Gene Causes the Rare Rhizomelic Chondrodysplasia Punctata Type 3: A Case Report.

Authors:  Aiman M Shawli; Abdulaziz T Nazer; Yasir Khayyat; Mohammed G Alqurashi; Fahad Hakami
Journal:  Cureus       Date:  2021-12-20

6.  Genetic epidemiology approach to estimating birth incidence and current disease prevalence for rhizomelic chondrodysplasia punctata.

Authors:  Tarik Luisman; Tara Smith; Shawn Ritchie; Karen E Malone
Journal:  Orphanet J Rare Dis       Date:  2021-07-06       Impact factor: 4.123

7.  Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata.

Authors:  Wedad Fallatah; Tara Smith; Wei Cui; Dushmanthi Jayasinghe; Erminia Di Pietro; Shawn A Ritchie; Nancy Braverman
Journal:  Dis Model Mech       Date:  2020-01-24       Impact factor: 5.758

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.